Gelesis Holdings, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yishai Zohar
- Full Time Employees
- 93
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 501 Boylston Street Boston MA United States of America 02116
- IPO Date
- Jan 14, 2022
- CIK
- 0001805087
- Website
- gelesis.com
- Similar Companies
- Business
- Gelesis Holdings, Inc. is a biotechnology company primarily engaged in the development and commercialization of innovative therapeutics for the treatment of obesity and related metabolic diseases. The company’s core product offerings center on the development of novel oral hydrogel technologies, particularly focusing on its flagship product, Plenity. Plenity is an FDA-cleared, non-systemic, oral hydrogel capsule designed to help adults with overweight or obesity manage their weight by promoting a feeling of fullness. Gelesis operates within the biopharmaceutical industry, delivering solutions that leverage proprietary hydrogel-based medical devices aimed at improving metabolic health outcomes. Gelesis conducts its business globally, with a particular emphasis on the United States market and expanding commercial operations in other regions. Founded in 2006, the company is headquartered in Boston, Massachusetts. Gelesis not only develops but also markets products under its proprietary technology platforms, delivering treatments that combine scientific innovation with a focus on patient safety and efficacy. In the last 1-2 years, Gelesis has undergone significant strategic developments, including commercial expansion efforts for Plenity, establishing new partnerships to enhance distribution and market penetration, and advancing its clinical pipeline with new product candidates targeting obesity and related conditions. The company has also focused on scaling its commercial operations and market awareness campaigns to solidify its presence in the weight management segment. Additionally, Gelesis has been engaging in capital-raising activities to support its growth initiatives and research programs, reflecting a strategic push to broaden its therapeutic portfolio and maintain competitive positioning in the biotechnology market. Overall, Gelesis Holdings, Inc. operates in the biotechnology and healthcare industry segments, targeting healthcare providers, patients dealing with obesity, and related chronic disease markets. Its core strengths lie in its innovative hydrogel technology platform, with ongoing development programs to expand its indications and applications. The company’s sustained focus on research, commercialization, strategic partnerships, and capital investments underscore its commitment to becoming a leader in metabolic disease therapeutics.
GLS Italy strengthens its network of pick-up points in partnership with Quadient
Royal Mail's sister business GLS to buy 20% stake in Greece's ACS for $80 million
Royal Mail, GLS need sizable investments soon, billionaire suitor Kretinsky says
Cell Reports Medicine Publication Demonstrates How Gelesis' Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies
Gelesis Holdings, Inc. (GLS) Q3 2022 Earnings Call Transcript
Gelesis Reports Third Quarter 2022 Results
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity Week
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome
Gelesis Holdings, Inc. (GLS) CEO Yishai Zohar on Q2 2022 Results - Earnings Call Transcript
Gelesis Reports Second Quarter 2022 Results
Gelesis Holdings' (GLS) CEO Yishai Zohar on Q1 2022 Results - Earnings Call Transcript
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases
Gelesis Holdings, Inc. (GLS) CEO Yishai Zohar on Q4 2021 Results - Earnings Call Transcript
Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook
Gelesis to Report Full Year 2021 Financial Results on March 24, 2022